| 📌 The essentials PDUFA date: Q2 2026. The FDA is expected to rule on datopotamab deruxtecan (Dato-DXd, brand name Datroway), developed by AstraZeneca and Daiichi Sankyo, for first-line treatment of metastatic triple-negative breast cancer in patients ineligible for immunotherapy. The clinical case: In the TROPION-Breast02 Phase 3 trial, Dato-DXd extended median progression-free survival from 5.6 months to 10.8 months and overall survival from 18.7 months to 23.7 months versus chemotherapy. Both primary endpoints reached statistical significance. What makes it significant: If approved, Dato-DXd would be the first non-chemotherapy, non-immunotherapy first-line option for this specific population. This post covers the biology of TNBC, who is immunotherapy-ineligible and why, the full TROPION-Breast02 data including important context, the safety profile, and what approval would mean for patients navigating this diagnosis. |
|---|
Triple-negative breast cancer is defined by what it lacks: no estrogen receptor, no progesterone receptor, no HER2 amplification. Those absences mean that the targeted therapies which have transformed outcomes in other breast cancer subtypes do not apply here. For decades, chemotherapy was the only systemic option. Then, in 2020, immunotherapy arrived for patients whose tumors expressed the PD-L1 protein. A meaningful advance for those patients. But not everyone qualifies.
Patients with metastatic TNBC who are ineligible for immunotherapy have historically had the fewest options and the worst outcomes of any breast cancer population. Their first-line treatment has remained standard cytotoxic chemotherapy, with all the toxicity that entails and a median overall survival below two years.
Datopotamab deruxtecan (Dato-DXd, brand name Datroway) is now seeking to change that. Developed by AstraZeneca and Daiichi Sankyo, the drug already received FDA approval in January 2025 for a different breast cancer subtype (HR-positive, HER2-negative). Now it has Priority Review for a new indication: first-line treatment of metastatic TNBC in patients who are not candidates for immunotherapy. The PDUFA date falls in Q2 2026. The Phase 3 TROPION-Breast02 trial, published in the Annals of Oncology in April 2026, produced results that oncologists are calling a potential new standard of care.
Triple-Negative Breast Cancer: The Biology, the Burden, and the Disparities
Triple-negative breast cancer accounts for approximately 15% of all breast cancer diagnoses in the United States, roughly 35,000 new cases per year. Despite representing a minority of breast cancer cases, it accounts for a disproportionate share of breast cancer deaths because of its aggressive biology, its relative resistance to treatment, and its tendency to be diagnosed at younger ages and at more advanced stages.
The racial disparities in TNBC are well documented and clinically significant. Black women are diagnosed with TNBC at roughly twice the rate of white women. They are more likely to be diagnosed at younger ages and more advanced stages. And despite these higher incidence rates, access to specialist oncology care and novel therapies has historically been unequal. Any advance in TNBC outcomes is therefore not just an oncologic milestone but a health equity issue.
| Who is ineligible for immunotherapy in TNBC, and why this population matters Since 2020 and 2021, PD-L1 checkpoint inhibitors (atezolizumab and then pembrolizumab) have been approved as first-line options for metastatic TNBC. Pembrolizumab with chemotherapy is now the standard of care for PD-L1-positive metastatic TNBC, and it produces a meaningful survival benefit in that population. However, PD-L1 positivity is not universal in TNBC. Depending on the assay and scoring method used, approximately 40 to 60 percent of metastatic TNBC patients have PD-L1-positive tumors. The remainder, along with patients who cannot receive immunotherapy due to autoimmune disease, organ transplant status, or other contraindications, fall into the immunotherapy-ineligible category. TROPION-Breast02 enrolled specifically and exclusively these patients. This is the population for which first-line treatment has remained unchanged at standard chemotherapy for decades, and the population for which Dato-DXd is seeking approval. |
What Is Dato-DXd and How Does It Work?
Datopotamab deruxtecan is an antibody-drug conjugate, part of the same drug class as trastuzumab deruxtecan (Enhertu/T-DXd) and sacituzumab govitecan (Trodelvy). All ADCs share the same general architecture: an antibody that recognizes a target protein on cancer cell surfaces, linked to a chemotherapy payload. The antibody finds the cancer cell, binds to it, is internalized, and releases the payload inside the cell.
Dato-DXd’s target is TROP2 (trophoblast cell-surface antigen 2), a protein expressed at high levels on the surface of many solid tumors, including the majority of TNBC tumors. The payload is DXd, a topoisomerase I inhibitor derived from exatecan. When the ADC is internalized into TROP2-expressing tumor cells, the linker is cleaved and DXd is released inside the cell, interfering with DNA replication and causing cancer cell death.
The linker technology is an important distinguishing feature. The cleavable tetrapeptide-based linker used in Dato-DXd is designed to be stable in the bloodstream but cleaved efficiently inside cells. This stability reduces off-target payload release in circulation, which contributes to a lower rate of hematologic toxicity compared to some earlier ADC platforms. The same DXd payload and linker technology is used in T-DXd (Enhertu), which explains the shared class safety signal of interstitial lung disease and stomatitis across both drugs.
| Dato-DXd versus sacituzumab govitecan (Trodelvy): both target TROP2, but differently Sacituzumab govitecan (Trodelvy) is the other FDA-approved TROP2-directed ADC in breast cancer. It is approved for previously treated metastatic TNBC and for HR-positive HER2-negative metastatic breast cancer. Both it and Dato-DXd target TROP2, but they use different antibodies, different payloads (SN-38 for sacituzumab vs. DXd for datopotamab), and different linker technologies. The practical difference shows up in the safety profile: sacituzumab govitecan has higher rates of hematologic toxicity (neutropenia, diarrhea) while Dato-DXd’s signature toxicities are stomatitis and ocular surface events. Neither has been compared head-to-head in TNBC. They occupy different approved settings, and the question of how to sequence them in the metastatic TNBC treatment landscape is one the field will need to work out as approvals evolve. The panel discussion at OncLive noted that differences in linker technology and payload between the two drugs may influence clinical outcomes, but no definitive comparative data exists. Clinicians should be familiar with both safety profiles to counsel patients appropriately. |
TROPION-Breast02: Design and Full Results
Trial design
TROPION-Breast02 (NCT05374512) was a randomized, open-label, international Phase 3 trial conducted across multiple countries. Between May 2022 and June 2024, 644 patients with previously untreated, locally recurrent inoperable or metastatic TNBC who were not candidates for PD-1/PD-L1 inhibitors were randomized 1:1 to Dato-DXd (6 mg/kg intravenously every 3 weeks, n=323) or investigator’s choice of chemotherapy (ICC, n=321). ICC options included paclitaxel, nab-paclitaxel, carboplatin, capecitabine, or eribulin mesylate. Randomization was stratified by geographic region, disease-free interval, and PD-L1 status.
The trial had dual primary endpoints: progression-free survival by blinded independent central review (BICR) per RECIST 1.1, and overall survival. Both primary endpoints were required to demonstrate statistical significance for the trial to be considered successful. Achieving both is a notable distinction in a disease setting where OS data is often immature at the time of initial analysis.
Efficacy results
| Efficacy endpoint | Dato-DXd (n=323) | Chemotherapy (n=321) |
| Median PFS (BICR) | 10.8 months (95% CI 8.6–13.0) | 5.6 months (95% CI 5.0–7.0) |
| PFS hazard ratio | 0.57 (95% CI 0.47–0.69; p<0.0001) | Reference |
| Risk reduction in progression/death | 43% | Reference |
| 12-month PFS rate | 45.6% | 25.6% |
| 18-month PFS rate | 32.7% | 16.8% |
| Median OS | 23.7 months | 18.7 months |
| OS hazard ratio | 0.79 (21% reduction in risk of death; p<0.05) | Reference |
| Median treatment duration | 6.7 months | 4.1 months |
| Patients on treatment at data cutoff | Longer than chemo arm | Shorter duration |
The PFS result is the most striking number: 10.8 versus 5.6 months is a near doubling of the time to disease progression or death. The 12-month PFS rates tell a related story: at one year, 45.6% of patients on Dato-DXd were progression-free, compared to 25.6% on chemotherapy. At 18 months, those rates were 32.7% versus 16.8%.
The OS result of 23.7 versus 18.7 months represents approximately five additional months of survival, with a statistically significant hazard ratio of 0.79. Having both PFS and OS meet statistical significance in the same trial is an important finding. Many oncology trials achieve PFS endpoints but fail to translate that into an OS benefit, sometimes because subsequent therapies after disease progression equalize outcomes across arms. TROPION-Breast02 demonstrated both.
The 6.7 versus 4.1 month median treatment duration favoring Dato-DXd is an indirect measure of tolerability: patients stayed on the experimental treatment longer, suggesting the drug was manageable enough to continue. That observation is supported by the safety data.
For patients with ER-positive disease, a separate PROTAC-based therapy is simultaneously under FDA review. Read about it here.
Safety: A Different Toxicity Profile Than Chemotherapy
Dato-DXd does not look like chemotherapy in its safety profile. Where chemotherapy predominantly causes hematologic toxicity (neutropenia, anemia, febrile neutropenia), Dato-DXd’s characteristic adverse effects are mucosal (stomatitis) and ocular. This difference matters for patient counseling and clinical management.
| Safety metric | Dato-DXd | Chemotherapy (ICC) |
| Any treatment-related adverse event | 93% | 83% |
| Grade 3 or higher TRAEs | 33% | 29% |
| Serious treatment-related AEs | 9% | 8% |
| Discontinuation due to TRAEs | 4% | 7% |
| Treatment-related deaths | 0 | 0 |
| Stomatitis (all grade) | 57% | Lower |
| Nausea (all grade) | 45% | Lower |
| Alopecia (all grade) | 41% | 21% |
| Ocular surface events (grade 1, dry eye/keratitis) | 24% | 3% |
| ILD/pneumonitis (drug-related, adjudicated) | Less than 1% | Less than 1% |
| Hematologic toxicity (neutropenia, anemia) | Lower than chemo arm | Predominant toxicity |
Several aspects of this safety data are worth emphasizing for clinical context. First, discontinuation due to treatment-related adverse events was actually lower with Dato-DXd (4%) than with chemotherapy (7%). This means patients on the experimental arm were less likely to stop treatment because of toxicity despite the higher overall rate of any adverse event. The profile is different, not simply worse.
Second, stomatitis at 57% is high in absolute terms but predominantly low-grade. The OncLive panel reviewing these results noted that proactive oral care management, including steroid-based mouthwash protocols (expanded from the SWISH trial experience with everolimus), can substantially reduce the incidence and severity of high-grade stomatitis. Institutions implementing Dato-DXd will need nursing education focused on stomatitis prevention and grading.
Third, ocular surface events (dry eye, keratitis) at 24% are almost entirely grade 1 and manageable with lubricating eye drops and ophthalmologic monitoring. The ILD rate of less than 1% is consistent with the known Dato-DXd class signal, lower than what is seen with T-DXd at current doses. ILD monitoring, prompt evaluation of respiratory symptoms, and early intervention with corticosteroids for confirmed cases remain important clinical requirements.
Context: How This Fits Into the TNBC Treatment Landscape
If approved, Dato-DXd would become the first non-chemotherapy, non-immunotherapy first-line option for metastatic TNBC patients who cannot receive checkpoint inhibitors. The treatment landscape for this population would shift in two meaningful ways.
First, the starting line for subsequent treatment sequencing changes. Patients who progress on first-line Dato-DXd will have had an ADC with a specific toxicity profile and resistance pattern. How sacituzumab govitecan (Trodelvy), currently approved in previously treated metastatic TNBC, performs after Dato-DXd progression is not established. This sequencing question will drive post-approval research.
Second, the ADC revolution in breast cancer treatment is now reaching the TNBC immunotherapy-ineligible population specifically. T-DXd reshaped HER2-positive and HER2-low metastatic breast cancer. Sacituzumab govitecan improved outcomes in previously treated TNBC. Dato-DXd, if approved, would extend ADC-based first-line treatment into a subgroup previously limited to cytotoxic chemotherapy.
| What the TROPION-Breast01 trial (HR+/HER2- breast cancer) can teach us here Dato-DXd’s January 2025 FDA approval for HR-positive, HER2-negative metastatic breast cancer came from the TROPION-Breast01 trial. That trial met its primary PFS endpoint but did not achieve statistical significance on OS. The explanation offered by investigators was that subsequent ADC treatment in the control arm after disease progression may have equalized survival outcomes. TROPION-Breast02 in TNBC is different in a clinically important way: it achieved statistical significance on both PFS and OS. This distinction matters for the regulatory submission and for clinician confidence. When a trial achieves the survival endpoint and not just the surrogate, the benefit-risk assessment is on firmer ground. The difference in OS outcomes between the two trials also highlights how patient population and available subsequent therapies shape survival data. TNBC patients in TROPION-Breast02 had fewer subsequent treatment options after progression compared to HR+ patients, which may have allowed the OS benefit to emerge more clearly in this trial. |
Dato-DXd (Datroway) is currently FDA-approved for HR-positive, HER2-negative breast cancer. The TNBC indication is under Priority Review with a PDUFA date in Q2 2026. Until a decision is issued, this drug is not available for TNBC outside of clinical trials. Priority Review means the FDA will aim to complete its review within 6 months of application acceptance, prioritizing drugs that may offer major advances over available therapy.
What to Discuss With Your Oncologist Now
- If you have recently been diagnosed with metastatic TNBC, ask your oncologist whether your tumor has been tested for PD-L1 expression and what the result means for your first-line treatment options.
- If you are PD-L1-positive and immunotherapy-eligible, pembrolizumab plus chemotherapy is the current standard of care and is not affected by this FDA decision.
- If you are immunotherapy-ineligible, ask your oncologist about clinical trials for which you may be eligible, including ongoing Dato-DXd studies and other ADC programs in TNBC. ClinicalTrials.gov is the best place to search for open studies.
- If Dato-DXd receives FDA approval in Q2 2026, it will immediately become available as an alternative first-line option to standard chemotherapy for immunotherapy-ineligible patients. NCCN guideline updates typically follow promptly after FDA approval.
We will update this post when the FDA issues its ruling.
For patients and families navigating a TNBC diagnosis, the most important resource is an oncologist at a center with experience in breast cancer clinical trials and access to current molecular testing. The National Cancer Institute’s Cancer Center directory can help identify specialized centers. Susan G. Komen and the Triple Negative Breast Cancer Foundation maintain updated patient-facing resources on treatment options, clinical trials, and support programs.
Sources
OncLive Phase 3 results: TROPION-Breast02 Data Support Dato-DXd as New First-Line SOC in Triple-Negative Breast Cancer. OncLive. April 2026.
OncLive Priority Review: FDA Grants Priority Review to Frontline Dato-DXd for Metastatic TNBC Ineligible for Immunotherapy. OncLive. 2026.
OncLive panel discussion: Findings for Frontline Dato-DXd From TROPION-Breast02 in Immunotherapy-Ineligible TNBC. OncLive. May 2026.
OncoDaily safety summary: Datopotamab Deruxtecan Improves PFS and OS in First-Line Advanced TNBC in TROPION-Breast02. OncoDaily. April 2026.
Cancer Nursing Today: Datopotamab Deruxtecan Expands First-Line Treatment Options in Metastatic TNBC. May 2026.
CancerNetwork overview: How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research. CancerNetwork. May 2026.
AstraZeneca Priority Review announcement: DATROWAY granted Priority Review in the US as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy. AstraZeneca. 2026.
TROPION-Breast01 context: FDA approves datopotamab deruxtecan for HR+/HER2- breast cancer. FDA.gov. January 2025.
Patient resources: NCI Cancer Center directory | Susan G. Komen | TNBC Foundation
| Disclaimer: Health Evidence Digest provides general information about clinical trials and FDA regulatory processes for educational purposes. This content is not a substitute for professional medical advice. Datopotamab deruxtecan (Dato-DXd/Datroway) is not yet FDA-approved for triple-negative breast cancer. Treatment decisions for metastatic TNBC should be made in close consultation with a qualified oncologist who can account for your individual diagnosis and treatment history. |
|---|
Leave a Reply